About US
Contact us
-
AMA lines up against pharma's pay-to-delay dealsThe Federal Trade Commission has a powerful new ally in its quest to quash "pay to delay" patent settlements: The American Medical Association. As Forbes reports, the doctors' association now officia2012/11/15
-
Genzyme resolves shortage of cancer drug ThyrogenA drug shortage has been solved. Genzyme is now able to supply its thyroid cancer treatment, Thyrogen, even as it moves further into thyroid cancer treatment with a new biomarker that helps doctors d2012/11/15
-
Merck gives up on prospective Januvia-Lipitor comboJust three months after quietly snuffing its late-stage development program for the cholesterol combo MK-0524B, Merck ($MRK) has doused development efforts on a new therapy combining its diabetes dru2012/11/14
-
New drug significantly lowers bad cholesterolFor many people with high cholesterol, statins serve as the first line of treatment. However, some patients are unable to effectively reduce their low-density lipoprotein cholesterol (LDL cholester2012/11/14
-
Pharma firms choosing to run more phase-IV trialsThere has been an increase in the number of phase-IV clinical trials being initiated voluntarily by pharmaceutical companies, new research shows. Phase-IV trials are sometimes required by regulator2012/11/13
-
Takeda to acquire Envoy TherapeuticsTakeda Pharmaceutical Company's wholly-owned subsidiary, Takeda America Holdings, has entered into a definitive agreement to acquire Envoy Therapeutics and its bacTRAP drug discovery platform. The2012/11/13
-
Hospira returning to market with sedative propofolHospira's ($HSP) inability to provide propofol has been one reason the sedative has been on shortage lists for some time. Now, Hospira says it should be back in the market with a significant supply b2012/11/12
-
CVS shucking more drugs from its coverage listBeginning in January, the list of drugs CVS Caremark's ($CVS) pharmacy-benefit business will refuse to cover will grow to about 50. The company is adding 17 drugs to nearly three dozen it already2012/11/12
-
GSK, XenoPort part ways after Horizant disappointmentGlaxoSmithKline ($GSK) is punting on Horizant. The U.K.-based drugmaker is kicking the restless legs syndrome drug back to partner XenoPort after a series of setbacks, including disappointing sales2012/11/9
-
Sanofi halves the cost of controversial new cancer drug ZaltrapSanofi ($SNY) has put Zaltrap on sale for 50% off. The colorectal cancer drug isn't an overstock, but a brand-new product, approved by FDA in August. Like most new cancer drugs these days, it's expe2012/11/9